Abstract
Androgen receptor blockade is a cornerstone of treatment for prostate cancer. Despite castrate levels of testosterone, activation of the androgen receptor remains an important mediator of disease progression in the androgen "independentg" state. Thus, maximal blockade of androgen receptor signaling is a continual goal in the management of castration-resistant prostate cancer. In this review we will discuss how various aspects of androgen receptor signaling are being targeted for therapeutic development in castration-resistant prostate cancer. These include direct androgen receptor inhibitors, inhibitors of adrenal androgen synthesis, and a dual 5α-reductase isoenzyme inhibitor.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 11-14 |
| Number of pages | 4 |
| Journal | Cancer Journal (United States) |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Abiraterone
- Androgen receptor
- BMS-641988
- Dutasteride
- Ketoconazole
- MDV3100
Fingerprint
Dive into the research topics of 'Novel concepts in androgen receptor blockade'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS